GenVec Company Profile (NASDAQ:GNVC)

About GenVec (NASDAQ:GNVC)

GenVec logoGenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GNVC
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $6.74
  • 200 Day Moving Avg: $5.80
  • 52 Week Range: $0.27 - $10.44
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.57
  • P/E Growth: 0.000
  • Net Margins: -3,748.25%
  • Return on Equity: -648.22%
  • Return on Assets: -271.77%
  • Current Ratio: 2.10%
  • Quick Ratio: 2.10%
  • Average Volume: 28,534 shs.
  • Beta: 3.34

Frequently Asked Questions for GenVec (NASDAQ:GNVC)

What is GenVec's stock symbol?

GenVec trades on the NASDAQ under the ticker symbol "GNVC."

When did GenVec's stock split? How did GenVec's stock split work?

GenVec shares reverse split on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.

How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) issued its quarterly earnings results on Friday, November, 4th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. The firm had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million. GenVec had a negative return on equity of 648.22% and a negative net margin of 3,748.25%. View GenVec's Earnings History.

Where is GenVec's stock going? Where will GenVec's stock price be in 2017?

2 analysts have issued twelve-month target prices for GenVec's stock. Their forecasts range from $7.00 to $7.00. On average, they expect GenVec's share price to reach $7.00 in the next year. View Analyst Ratings for GenVec.

Who are some of GenVec's key competitors?

Who are GenVec's key executives?

GenVec's management team includes the folowing people:

  • Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
  • Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
  • William N. Kelley M.D., Independent Director
  • Stefan D. Loren Ph.D., Independent Director
  • Quinterol J. Mallette M.D., Independent Director
  • Michael S. Richman, Independent Director
  • Marc R. Schneebaum, Independent Director

How do I buy GenVec stock?

Shares of GenVec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenVec's stock price today?

One share of GenVec stock can currently be purchased for approximately $7.19.

MarketBeat Community Rating for GenVec (NASDAQ GNVC)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GenVec (NASDAQ:GNVC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.00 (2.68% downside)

Analysts' Ratings History for GenVec (NASDAQ:GNVC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/25/2017HC WainwrightDowngradeHold$7.00N/AView Rating Details
1/25/2017Rodman & RenshawDowngradeBuy -> Neutral$15.00 -> $7.00N/AView Rating Details
7/26/2016Roth CapitalReiterated RatingBuy$80.00 -> $20.00N/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for GenVec (NASDAQ:GNVC)
Earnings by Quarter for GenVec (NASDAQ:GNVC)
Earnings History by Quarter for GenVec (NASDAQ GNVC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 2016($0.08)($0.05)$0.07 million$0.17 millionViewN/AView Earnings Details
8/5/2016Q116($0.10)($0.06)$0.12 million$0.03 millionViewN/AView Earnings Details
5/12/2016Q1 2016($0.09)($0.11)$0.18 million$0.29 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.10)$0.21 million$0.16 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.11)($0.09)$0.15 million$0.19 millionViewN/AView Earnings Details
8/7/2015Q215($0.10)($0.11)$0.38 million$0.13 millionViewN/AView Earnings Details
5/8/2015Q115($0.06)($0.09)$0.91 million$0.41 millionViewN/AView Earnings Details
3/24/2015Q414$0.08$0.11$3.33 million$3.50 millionViewListenView Earnings Details
11/12/2014Q314($0.09)($0.10)$1.00 million$0.25 millionViewN/AView Earnings Details
8/12/2014Q214($0.15)($0.10)$0.13 millionViewN/AView Earnings Details
5/12/2014Q114$0.04($0.07)$2.00 million$2.10 millionViewN/AView Earnings Details
3/28/2014Q413($0.16)($0.07)$1.52 million$0.15 millionViewListenView Earnings Details
11/12/2013Q313($0.23)$2.10 million$1.60 millionViewN/AView Earnings Details
11/9/2012Q312($0.32)($0.30)$2.90 million$2.13 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GenVec (NASDAQ:GNVC)
Current Year EPS Consensus Estimate: $-2.500 EPS
Next Year EPS Consensus Estimate: $-2.800 EPS


Dividend History for GenVec (NASDAQ:GNVC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GenVec (NASDAQ:GNVC)
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 6.22%
Insider Trades by Quarter for GenVec (NASDAQ:GNVC)
Institutional Ownership by Quarter for GenVec (NASDAQ:GNVC)
Insider Trades by Quarter for GenVec (NASDAQ:GNVC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Douglas J SwirskyCEOBuy10,000$0.50$5,000.00View SEC Filing  
12/14/2015Douglas J SwirskyCEOBuy5,000$2.00$10,000.00View SEC Filing  
11/16/2015Stefan LorenDirectorBuy4,000$1.93$7,720.00View SEC Filing  
8/11/2015Douglas E BroughInsiderBuy4,600$2.34$10,764.00View SEC Filing  
5/27/2014Ecor1 Capital, LlcMajor ShareholderBuy24,140$2.24$54,073.60View SEC Filing  
3/28/2014Ecor1 Capital, LlcMajor ShareholderBuy122,273$2.55$311,796.15View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GenVec (NASDAQ:GNVC)
Latest Headlines for GenVec (NASDAQ:GNVC)
DateHeadline logoHead to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC) - August 30 at 9:12 AM logoIntrexon Integrates Leading Adenoviral Gene Delivery Technology with ... - June 17 at 10:55 PM logoIntrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition - June 16 at 6:15 PM logoGenVec Inc (GNVC) Short Interest Update - June 4 at 9:46 AM logoGenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 6:10 PM logo GenVec Inc (GNVC) Receives Consensus Rating of "Hold" from Brokerages - May 12 at 10:56 AM logoHow These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma - April 28 at 10:35 AM logoGenVec (GNVC) Given Daily News Impact Rating of 0.35 - April 28 at 12:06 AM logoGenVec (GNVC) Receiving Somewhat Favorable Media Coverage, Report Shows - April 24 at 1:28 PM logoSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc. - April 17 at 9:21 PM logoGENVEC INC Financials - March 10 at 6:39 PM logoGENVEC INC Files SEC form 10-K, Annual Report - March 6 at 5:07 PM logoWeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release) - February 8 at 11:04 PM logoWeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - February 8 at 11:04 PM logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And Encourages Investors To Contact The Firm For Additional Information - February 6 at 5:33 PM logoGENVEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenVec, Inc. - February 2 at 6:04 PM logoRodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - - January 26 at 6:57 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of GenVec, Inc. to Intrexon Corporation is Fair to Shareholders - GNVC - January 26 at 6:56 PM logoIntrexon To Buy GenVec For $7 a Share (XON, GNVC) - January 25 at 4:51 PM logoGenVec downgraded by Rodman & Renshaw - January 25 at 4:51 PM logoIntrexon To Buy GenVec In Stock Deal For $7/Shr - January 25 at 4:51 PM logoGenVec Inc. (GNVC) Is Up Sharply After Bought By Intrexon - January 24 at 6:14 PM logoGENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit - January 24 at 6:14 PM logoEnteroMedics and GenVec Post Substantial Gains as the NASDAQ is Pushed to Record High - January 10 at 6:27 PM logoEast Coast biotech company licenses Washington U technology - January 9 at 4:18 PM logoGenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. Louis - January 5 at 6:28 PM logo8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting - January 5 at 6:28 PM



GenVec (GNVC) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff